Newronika Secures €8.4M Series A Funding to Advance First-Ever Closed-Loop DBS System for Parkinson’s Disease

VCBeat (WeChat ID: vcbeat) has learned that Newronika, a spin-off from the University of Milan and the world-class Milan-based neurological research center Polimento, has completed an €8.4 million Series A financing round. The round was led by the French venture capital fund Omnes, with existing investors Innogest Capital and Indaco Venture Partners SGR participating on behalf of Indaco Ventures I and Atlante Ventures funds, respectively. Additionally, F3F and an undisclosed family office also joined the syndicate.

Newronika has developed a closed-loop system for deep brain stimulation (DBS), the first of its kind in the field. This technology will be applied to patients with Parkinson’s disease, with further exploration of additional indications planned in the future. The financing will enable Newronika to complete its first-in-human clinical study, which will seek both CE marking and FDA approval.

“Newronika is the first company to develop a closed-loop system for treating Parkinson’s disease,” said Lorenzo Rossi, CEO of Newronika. “Since Medtronic invented the first deep brain stimulation (DBS) system more than 20 years ago, such related solutions have been needed and anticipated by the medical community. Currently, Newronika’s technology can record neural signals and adapt deep brain stimulation in real time. Arguably, Newronika’s closed-loop system is a game-changer in neurology, paving the way for numerous potential applications. We aim to establish a platform that enables our technology to be applied across a range of conditions, from Parkinson’s disease to traumatic brain injury.”

Currently, deep brain stimulation (DBS) has been widely used in clinical practice to treat movement disorders caused by diseases such as Parkinson’s disease. It also demonstrates promising application prospects in the treatment of other central nervous system disorders, including refractory epilepsy and intractable obsessive-compulsive disorder. After more than 30 years of research involving clinical applications, animal experiments, and computational model simulations, the mechanisms underlying DBS have gradually become clearer.

Alain Garcinuno, Chief Financial Officer of Newronika, stated: “This round of financing has propelled Newronika directly into the global competition in DBS technology, positioning our company as a major contender.”

Newronika is a spin-off company from the world-leading neurological research institution, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, and the University of Milan. Leveraging its innovative technologies to restore brain and body function, Newronika translates its profound expertise in biosignal decoding into clinical practice, with the aim of developing novel therapies and improving existing ones. The company boasts an interdisciplinary team spanning neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnology.

(Compiled by Ning Chen)